{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-116853","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.199641+00:00","generated_at":"2026-05-30T10:32:39.292816+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prelude Therapeutics PRT3789 Phase 1 interim data: 4 PRs; DAC program preclinical proof-of-concept","bullets":["Interim Phase 1 results: 4 confirmed partial responses (2 esophageal, 2 NSCLC) out of 26 evaluable SMARCA4 loss-of-function patients.","PRT3789 generally well-tolerated; no dose-limiting toxicities or drug-related SAEs; higher doses (≥212 mg) show deeper SMARCA2 degradation.","Combination with docetaxel shows acceptable safety profile; preclinical data show synergy with chemo in SMARCA4-mutant NSCLC models.","First preclinical proof-of-concept for SMARCA2/4 dual degrader antibody conjugates (DACs): anti-PSMA DACs show efficacy and tolerability in xenograft models."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-116853","json":"https://secwatch.observer/filing/0000950170-24-116853.json","markdown":"https://secwatch.observer/filing/0000950170-24-116853.md","text":"https://secwatch.observer/filing/0000950170-24-116853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024116853/0000950170-24-116853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024116853/prld-20241024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:32:39.292816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}